Intranasal Vaccine Against Lyme Disease
莱姆病鼻内疫苗
基本信息
- 批准号:10491410
- 负责人:
- 金额:$ 98.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-12 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AdultAffectAmericanAnimal ModelAntigensBiological AssayBorrelia burgdorferiCOVID-19COVID-19 vaccineCenters for Disease Control and Prevention (U.S.)Clinical TrialsDataDevelopmentDoseElderlyEpitopesGeneticHumanImmune responseImmunityImmunizationImmunization ScheduleImmunizeImmunoglobulin GInfectionIntranasal AdministrationInvestigational DrugsLaboratoriesLeadLengthLongevityLyme DiseaseLyme Disease VaccinesMethodsModelingMonkeysMusNeedlesNew Drug ApprovalsNymphOspA proteinOspA vaccineParainfluenzaPerformancePhasePhase I Clinical TrialsPrimatesProductionResearchSafetyScheduleSeedsSelf AdministrationSmall Business Innovation Research GrantSpecific qualifier valueTechnologyTicksTimeLineTissuesTrademarkVaccinationVaccinesVector-transmitted infectious diseaseVero CellsViral Vectoraluminum sulfatebasecell bankcommercializationdelivery vehicleimmunogenicimmunogenicitynonhuman primatenovelnovel vaccinespre-clinical assessmentpreclinical studypreventresponsesubcutaneoustick transmissionvaccination protocolvaccine accessvaccine candidatevaccine deliveryvaccine efficacyvaccine hesitancyvector-induced
项目摘要
ABSTRACT
We propose to develop intranasal, parainfluenza 5 (PIV5) viral-vector delivered vaccines
against human Lyme disease (LD) to be administered using a prime-boost schedule, for the US
market. A recent new estimate of LD by the CDC places the new number at 476,000 annual
cases, up from 329,000 in 2015 which strongly suggests that the number of Americans affected
by this vector-borne disease is increasing. Currently, there is no human Lyme Disease vaccine
available in the market. A prime-boost vaccination with an intranasal immunogen is a scientific
and technologic advance over best vaccination protocols in development for LD that currently
rely on parenteral inoculation of a minimum of 3 doses over 1 year. Our preliminary studies
show that intranasal administration of a modified OspA vaccine delivered by the laboratory
strain WR-PIV5 viral vector (WR-PIV5-OspABPBPk) via prime-boost (2 doses), produces an
immune response that is 100% protective against tick transmitted B. burgdorferi infection in
mice challenged 4 months after the 1st dose. PIV5 is a safe delivery vector used to develop
many vaccines, one of which is undergoing a human clinical trial. The commercialization
potential and societal impact of developing a novel, safe and efficacious LD vaccine that can be
delivered by a non-invasive method is highly significant given that it may induce more durable
immune responses, it could diminish vaccine hesitancy and increase vaccine compliance, and it
could enable self-administration of one or both doses. The novelty of the vaccine proposed in
this Direct to Phase II SBIR application relates to: 1) the use of a modified full length OspA
protein in which the putative autoantigenic epitope has been replaced; 2) a needle-free
intranasal delivery method in a safe, highly immunogenic viral vector; 3) the reduced number of
immunizations; 4) ease of administration; and 5) the potential to increase immunity longevity.
We propose to develop a new viral vector expressing OspABPBPk based on the PIV5 vaccine
strain (CPI) and evaluate intranasal vaccine efficacy in mice as compared to the WR-PIV5-
ABPBPk shown in preliminary results; we will also assess immunogenicity, safety and efficacy of
the best vaccine candidate in the non-human primate (NHP) model of Lyme disease; last, we
will perform studies required for Investigational New Drug (IND) regulatory approval by FDA.
Once the novel vaccine is shown to meet pre-set performance criteria specified in our
milestones (>80% efficacy in mice and non-human primate models), it will be trademarked as
LymeMist™ and the company will implement a plan to commercialize it.
摘要
我们建议开发鼻腔副流感5型(PIV5)病毒载体递送疫苗
抗人类莱姆病(LD)将在美国使用主要增强时间表进行管理
市场。美国疾病控制与预防中心最近对LD的最新估计显示,新的数字为每年476,000人
病例,高于2015年的329,000例,这有力地表明受影响的美国人的数量
由这种媒介传播的疾病正在增加。目前,还没有人类莱姆病疫苗
在市场上有售。用鼻腔免疫原加强接种是一种科学的方法
以及目前正在开发的LD最佳疫苗接种方案的技术进步
依靠非肠道接种,在一年内至少接种3剂。我们的初步研究
显示鼻腔注射实验室提供的改良OspA疫苗
WR-PIV5株病毒载体(WR-PIV5-OspABPBPk)经Prime-Boost(2剂),产生
对蜱传的伯氏杆菌感染有100%保护作用的免疫应答
小鼠在第一次服药后4个月接受挑战。PIV5是一种安全的传递媒介,用于开发
许多疫苗,其中一种正在进行人体临床试验。商业化
开发一种新的、安全有效的LD疫苗的潜在和社会影响
通过非侵入性方法交付是非常重要的,因为它可能会导致更持久的
免疫反应,它可以减少疫苗的犹豫不决,提高疫苗的依从性,而且它
可以实现一剂或两剂的自我给药。年提出的疫苗的新颖性
这种直接到第二阶段SBIR的应用涉及:1)使用经修改的全长OspA
假定的自身抗原表位已被替换的蛋白质;2)无针
一种安全、高免疫原性病毒载体的鼻腔给药方法;3)减少
免疫接种;4)易于管理;5)增加免疫寿命的可能性。
我们建议在PIV5疫苗的基础上开发一种表达OspABPBPk的新型病毒载体
并与WR-PIV5比较,评价小鼠鼻内疫苗的免疫效果。
ABPBPk在初步结果中显示;我们还将评估免疫原性、安全性和有效性
莱姆病非人类灵长类(NHP)模型的最佳候选疫苗;最后,我们
将进行FDA监管批准的研究新药(IND)。
一旦新型疫苗被证明符合我们的
里程碑(在小鼠和非人类灵长类动物模型中80%的疗效),它将被注册为
LymeMist™和该公司将实施一项将其商业化的计划。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Maria Gomes-Solecki其他文献
Maria Gomes-Solecki的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Maria Gomes-Solecki', 18)}}的其他基金
ImmunoPET Probes for the Imaging of Lyme Disease
用于莱姆病成像的免疫PET探针
- 批准号:
10802275 - 财政年份:2023
- 资助金额:
$ 98.85万 - 项目类别:
Antibody isotyping for discrimination of disease stage and diagnosis of early Lyme disease.
用于区分疾病阶段和诊断早期莱姆病的抗体同种型。
- 批准号:
10080461 - 财政年份:2020
- 资助金额:
$ 98.85万 - 项目类别:
Antibody isotyping for discrimination of disease stage and diagnosis of early Lyme disease.
用于区分疾病阶段和诊断早期莱姆病的抗体同种型。
- 批准号:
10204992 - 财政年份:2020
- 资助金额:
$ 98.85万 - 项目类别:
Field trial and modeling of transmission blocking vaccine to prevent Lyme disease
预防莱姆病的传播阻断疫苗的现场试验和建模
- 批准号:
10159849 - 财政年份:2019
- 资助金额:
$ 98.85万 - 项目类别:
Field trial and modeling of transmission blocking vaccine to prevent Lyme disease
预防莱姆病的传播阻断疫苗的现场试验和建模
- 批准号:
9815231 - 财政年份:2019
- 资助金额:
$ 98.85万 - 项目类别:
Field trial and modeling of transmission blocking vaccine to prevent Lyme disease
预防莱姆病的传播阻断疫苗的现场试验和建模
- 批准号:
10636945 - 财政年份:2019
- 资助金额:
$ 98.85万 - 项目类别:
Field trial and modeling of transmission blocking vaccine to prevent Lyme disease
预防莱姆病的传播阻断疫苗的现场试验和建模
- 批准号:
10415156 - 财政年份:2019
- 资助金额:
$ 98.85万 - 项目类别:
Lab on a chip point of care assay for the rapid serodiagnosis of Lyme disease
用于莱姆病快速血清诊断的芯片即时检测实验室
- 批准号:
9052111 - 财政年份:2011
- 资助金额:
$ 98.85万 - 项目类别:
Lab on a chip point of care assay for the rapid serodiagnosis of Lyme disease
用于莱姆病快速血清诊断的芯片即时检测实验室
- 批准号:
8195733 - 财政年份:2011
- 资助金额:
$ 98.85万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 98.85万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 98.85万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 98.85万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 98.85万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 98.85万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 98.85万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 98.85万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 98.85万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 98.85万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 98.85万 - 项目类别:
Studentship














{{item.name}}会员




